EUCTR2005-003885-40-IT
Active, not recruiting
Not Applicable
ACE-inhibitors and Angiotensin two receptor antagonists in IgA nephropathy with mild proteinuria
AZIENDA OSPEDALIERA PROVINCIALE DI LECCO0 sitesJanuary 15, 2007
ConditionsThe primary aim of the study consists in testing the hypothesis that blockade of the RAS may decrease the risk of developing adverse effects in patients with benign IgAN.Such blockade would first achieved with unique pharmacological class then shifting to the association of the two classes as soon as ineffective blockade is documentedMedDRA version: 9.1Level: SOCClassification code 10038359Term: Renal and urinary disorders
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- The primary aim of the study consists in testing the hypothesis that blockade of the RAS may decrease the risk of developing adverse effects in patients with benign IgAN.Such blockade would first achieved with unique pharmacological class then shifting to the association of the two classes as soon as ineffective blockade is documented
- Sponsor
- AZIENDA OSPEDALIERA PROVINCIALE DI LECCO
- Status
- Active, not recruiting
- Last Updated
- 13 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Angiotensin Converting Enzyme (ACE) inhibition for the preservation of renal function and patient survival in kidney transplantatioChronic kidney disease in renal transplant patientsUrological and Genital DiseasesChronic kidney diseaseISRCTN78129473Ottawa Hospital Research Institute (OHRI) (Canada) - formerly Ottawa Health Research Institute528
Recruiting
Not Applicable
Management of angiotensin inhibitors during the perioperative period.on-cardiac major surgeryNL-OMON25483niversity Medical Center Utrecht, The Netherlands3,200
Active, not recruiting
Phase 1
Angiotensin Converting Enzyme Inhibitor (ACE) Induced AngioedemaBERINERTRandomized, double-blind, two arms, multicenter, Phase III study of Berinert for treatment of ACE induced AngioedemaAngiotensin – Converting – Enzyme – Inhibitors (ACEi) are used in the treatment of several types of cardiovascular and renal diseases. A known side effect of ACEi are angioedema of the head and neck region. These can lead to severe dyspnoea and the need for intubation and are thought to be bradykinin mediated. Up until now there is no study-evaluated conservative therapeutic concept for the treatment of these patients.MedDRA version: 18.1Level: HLTClassification code 10002425Term: AngioedemasSystem Organ Class: 100000004870Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2012-001670-28-DEMedizinische Fakultät der Technischen Universität München52
Completed
Not Applicable
Angiotensin receptor blocker/Calcium antagonist combination therapy on diurnal blood pressure variatioHypertensionJPRN-UMIN000013050Jichi Medical University School of Medicine200
Completed
Not Applicable
The effects of angiotensin II receptor blockers (ARBs) on oxidative stress and atherosclerosis in patients with hypertension.Patients with hypertensionJPRN-UMIN000001300Second Department of Internal Medicine, Nagasaki University School of Medicine120